Atlas Trials

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Clinical trial NCT05568212 · RECRUITING

Trial details

NCT number
NCT05568212
Sponsor
Fondazione Ricerca Traslazionale
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small-cell Lung Cancer Patients
Start date
2022-05-02
Primary completion
2026-05-01
Enrollment
176

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.